In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor.
Publication/Presentation Date
8-1-2022
Abstract
INTRODUCTION: Patients with type-2 diabetes are twice as likely to suffer from acute myocardial infarction (AMI) and have a higher incidence of recurrent events than their non-diabetic counterparts. Ticagrelor is a platelet inhibitor known to reduce major adverse cardiovascular events (MACE) in AMI patients. This study measures the level and change in platelet activation and aggregation at the time of and following an AMI in patients with and without diabetes treated with ticagrelor.
MATERIALS/METHODS: P
RESULTS: Ninety-seven patients were prospectively enrolled (diabetes, N = 33; no diabetes, N = 64). No difference was observed in the expression of P-selectin and PAC-1 at any given point between diabetes and non-diabetes groups (p > 0.05). No difference was observed in the percentage of platelet bound to leukocytes at any measured timepoint between patients with and without diabetes (p > 0.05). Platelet leukocyte aggregation was suppressed during the acute phase compared to quiescence equally among both groups.
DISCUSSION: Ticagrelor demonstrated similar in-vivo effects on platelet activation and aggregation regardless of diabetes status in patients presenting with AMI.
Volume
145
First Page
107000
Last Page
107000
ISSN
1879-3649
Published In/Presented At
Singam, N. S. V., AlAdili, B., Amraotkar, A. R., Coulter, A. R., Singh, A., Kulkarni, S., Mitra, R., Daham, O. N., Smith, A. E., & DeFilippis, A. P. (2022). In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor. Vascular pharmacology, 145, 107000. https://doi.org/10.1016/j.vph.2022.107000
Disciplines
Medicine and Health Sciences
PubMedID
35623547
Department(s)
Department of Medicine
Document Type
Article
